C9orf72→RNA/Dipeptide Repeat Pathology→ALS/FTD — Causal Chain

Migration, Crosslink

📖

C9orf72→RNA/Dipeptide Repeat Pathology→ALS/FTD — Causal Chain

active

wiki page Created: 2026-04-02T07:19:57 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-c9orf72-rna-foci-dipepti

📖 Wiki Page

mechanism3056 wordssynced 2026-04-02

C9orf72→RNA Foci→Dipeptide Repeats→ALS/FTD: Causal Chain

Executive Summary

The [C9orf72](/genes/c9orf72) gene hexanucleotide repeat expansion (GGGGCC) is the most common genetic cause of [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS) and [frontotemporal dementia](/diseases/frontotemporal-dementia) (FTD), accounting for approximately 40% of familial ALS and 25% of familial FTD cases. This causal chain page traces the molecular pathway from the repeat expansion through multiple toxic mechanisms to clinical disease manifestation. PMID: 41763422

```mermaid
flowchart TD
subgraph Genetic["Genetic Defect"]
Expansion["G4C2 Repeat Expansion"]
Repeat1000["100-1000+ Repeats"]
Methylation["DNA/RNA Methylation"]
end

subgraph Toxicity1["RNA-Mediated Toxicity"]
RNAFoci["RNA Foci Formation"]
Splicing["Alternative Splicing Defects"]
RBPseq["RBP Sequestration"]
end

subgraph Toxicity2["Dipeptide Repeat Proteins"]
DPR["DPR Proteins (GP, GA, GR, PR, PA)"]
Nuclear["Nuclear Dysfunction"]
Translation["RAN Translation"]
end

subgraph Toxicity3["Nucleocytoplasmic Transport"]
NCT["Nucleocytoplasmic Transport Defect"]
Pore["Nuclear Pore Dysfunction"]
Import["Importin Dysfunction"]
end

subgraph Disease["Disease Outcome"]
Motor["Motor Neuron Degeneration"]
Frontotemporal["FTD Phenotype"]
ALS["ALS Phenotype"]
end

...

C9orf72→RNA Foci→Dipeptide Repeats→ALS/FTD: Causal Chain

Executive Summary

The [C9orf72](/genes/c9orf72) gene hexanucleotide repeat expansion (GGGGCC) is the most common genetic cause of [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS) and [frontotemporal dementia](/diseases/frontotemporal-dementia) (FTD), accounting for approximately 40% of familial ALS and 25% of familial FTD cases. This causal chain page traces the molecular pathway from the repeat expansion through multiple toxic mechanisms to clinical disease manifestation. PMID: 41763422

Mermaid diagram (expand to render)

The Genetic Foundation

Discovery and Epidemiology

The C9orf72 hexanucleotide repeat expansion was simultaneously discovered by two groups in 2011, representing one of the most significant genetic findings in ALS/FTD research [1](https://doi.org/10.1126/science.1208488) [2](https://doi.org/10.1038/nature10806): PMID: 41643021

| Parameter | Value |
|-----------|-------|
| Normal repeat range | 2-30 |
| Pathogenic threshold | >30-40 (penetrant) |
| Typical affected range | 100-1000+ repeats |
| Maximum observed | >10,000 repeats |

Population frequencies:

~1 in 400 individuals carry the expansion (unknown if all develop disease)
40% of familial ALS cases
25% of familial FTD cases
5-10% of sporadic ALS cases
~6% of sporadic FTD cases

Inheritance Pattern

The C9orf72 expansion shows:

Autosomal dominant inheritance with high but incomplete penetrance
Anticipation: earlier onset in successive generations (controversial)
Founder effect: common ancestor in many populations
Variable phenotypic expression: ALS-only, FTD-only, or ALS/FTD combination

Molecular Mechanisms

Mechanism 1: RNA-Mediated Toxicity

The expanded repeat is transcribed into abnormal RNA that forms nuclear foci, sequestering RNA-binding proteins (RBPs):[@pmid41341655] PMID: 41341655

Mermaid diagram (expand to render)

Sequestered proteins include:

[TDP-43](/proteins/tardbp-protein) (TARDBP) - [ALS/FTD](/diseases/amyotrophic-lateral-sclerosis) hallmark protein
[hnRNPA1/A2](/proteins/hnrnpa1-protein) - splicing regulators
[SRSF2](/proteins/srsf2-protein) - serine/arginine splicing factor
[Pur-alpha](/proteins/pur-alpha-protein) - RNA transport and translation

Consequences:

Loss of normal RBP function -> [splicing dysregulation](/mechanisms/nucleocytoplasmic-transport-defects)
RNA transport defects in neurons
Translation abnormalities
Formation of [stress granules](/mechanisms/stress-granules)

Mechanism 2: Dipeptide Repeat Proteins (RAN Translation)

The expansion can be translated in all six reading frames via Repeat-Associated Non-ATG (RAN) translation, producing five dipeptide repeat proteins:[@pmid41763422] PMID: 41763422

| DPR Type | Reading Frame | Toxicity | Localization |
|----------|---------------|-----------|---------------|
| Poly-GA (Gly-Ala) | Sense | High | Cytoplasmic |
| Poly-GR (Gly-Arg) | Sense | High | Nuclear |
| Poly-PR (Pro-Arg) | Sense | Very High | Nuclear |
| Poly-PA (Pro-Ala) | Antisense | Moderate | Cytoplasmic |
| Poly-GP (Gly-Pro) | Antisense | Moderate | Cytoplasmic |

The poly-GR and poly-PR proteins are particularly toxic, causing:

Nucleolar stress
Ribosome biogenesis defects
Translation dysregulation
Stress granule formation

Mermaid diagram (expand to render)

Mechanism 3: Nucleocytoplasmic Transport Defect

A landmark 2016 study demonstrated that C9orf72 dipeptide repeats directly disrupt nucleocytoplasmic transport (NCT)[@pmid41643021] [3](https://doi.org/10.1016/j.cell.2016.08.070): PMID: 41643021

Mermaid diagram (expand to render)

Nuclear pore complex (NPC) components affected:

Nup107, Nup133 (core scaffold proteins)
Nup98 (transport receptor binding)
Nup153 (basket component)
Importin alpha/beta family

Functional consequences:

Impaired TDP-43 import (contributing to cytoplasmic TDP-43 aggregates)
Reduced mRNA export from nucleus
Disrupted protein quality control
Enhanced vulnerability to cellular stress

Mechanism 4: C9orf72 Loss-of-Function

The expansion also reduces C9orf72 protein expression through multiple mechanisms: PMID: 41341655

Promoter methylation reducing transcription
RNA foci sequestering transcripts
Repeat-associated nonsense-mediated decay

C9orf72 is involved in:

Autophagosome formation
Lysosomal function
Endosomal trafficking

Loss of function contributes to:

Impaired autophagy-lysosome pathway
Decreased protein clearance
Enhanced accumulation of toxic proteins

Disease Phenotypes

ALS Phenotype

[C9orf72-associated ALS](/diseases/amyotrophic-lateral-sclerosis) is characterized by:

Typical onset: 50-60 years
Site of onset: Limb (most common), bulbar
Disease duration: 2-5 years (mean ~3 years)
Cognitive involvement: 30-40% develop FTD

Motor neuron involvement:

Upper motor neuron signs prominent
Combined UMN/LMN phenotype
Rapid progression compared to sporadic ALS

FTD Phenotype

[C9orf72-associated FTD](/diseases/frontotemporal-dementia) often presents as:

Subtype: Behavioral variant FTD (bvFTD) most common
Speech: Progressive aphasia variants possible
Motor features: Some develop ALS

Behavioral features:

Early disinhibition
Apathy
Loss of empathy
Food preference changes

ALS/FTD Spectrum

The C9orf72 expansion causes a continuous spectrum:

Pure ALS (~40%)
Pure FTD (~20%)
ALS+FTD (~40%)

Therapeutic Implications

Targeting the [C9orf72](/genes/c9orf72) Pathway

| Strategy | Approach | Status | Notes |
|---------|----------|--------|-------|
| [Antisense oligonucleotides](/technologies/antisense-oligonucleotides) | Silence C9orf72 expression | Preclinical | Reduces DPRs, improves phenotype |
| Small molecule transport | Restore NCT function | Preclinical | Targeting [nuclear pore](/mechanisms/nucleocytoplasmic-transport-defects) |
| DPR antibodies | Anti-GA immunotherapies | Preclinical | Remove toxic proteins |
| [Gene therapy](/technologies/gene-therapy) | AAV-C9orf72 | Preclinical | Restore function |

Biomarkers

| Biomarker | Change in C9orf72 Cases | Utility |
|-----------|------------------------|---------|
| CSF DPR (poly-GA) | Elevated | Diagnostic, tracking |
| CSF NfL | Elevated | Progression marker |
| MRI | Frontotemporal atrophy | Early detection |
| PET | Variable | Under investigation |

Clinical Trials

ASOs targeting C9orf72 in development (Wave, Ionis, others)
Focus on reducing both RNA foci and DPR production
Challenges: delivery to CNS, off-target effects

Stress Granule Dynamics and Cellular Stress Response

Stress Granule Formation in C9orf72 ALS

[Stress granules](/mechanisms/stress-granules) (SGs) are membrane-less organelles that form in response to cellular stress, serving as transient repositories for translationally stalled mRNAs and associated proteins. In [C9orf72-associated ALS/FTD](/diseases/amyotrophic-lateral-sclerosis), stress granule biology is profoundly disrupted through multiple mechanisms: PMID: 41763422

Key stress granule proteins affected in C9orf72 ALS:

G3BP1/2 - primary SG nucleators
TIA1 (T-cell-restricted intracellular antigen-1) - SG structural component
[TDP-43](/proteins/tardbp-protein) - abnormally recruited to SGs and sequestered
[FUS](/proteins/fus-protein) - another RNA-binding protein with SG localization

Mermaid diagram (expand to render)

Key stress granule proteins affected in C9orf72 ALS:

G3BP1/2 (Ras-GAP SH3 domain-binding proteins) - primary SG nucleators
TIA1 (T-cell-restricted intracellular antigen-1) - SG structural component
TDP-43 - abnormally recruited to SGs and sequestered
FUS - another RNA-binding protein with SG localization

C9orf72's Role in Stress Granule Regulation

[C9orf72](/genes/c9orf72) protein localizes to stress granules through its interaction with the [autophagy](/mechanisms/autophagy) adaptor proteins [p62/SQSTM1](/proteins/p62-protein) and [OPTN](/proteins/optn-protein). Loss of C9orf72 function disrupts this regulation: PMID: 41643021

Altered SG dynamics: C9orf72-deficient cells show prolonged SG persistence PMID: 41341655

Impaired SG clearance: [Autophagy](/mechanisms/autophagy)-mediated SG dissolution is compromised

Aberrant SG fusion: Abnormal coalescence of multiple SGs

Sequestration of essential proteins: Critical translational machinery trapped

Implications for Therapy

Stress granule-modulating strategies are actively being explored:

eIF2α dephosphorylation to restore translation
Small molecules targeting SG assembly/disassembly
[Autophagy enhancers](/mechanisms/autophagy) to improve SG clearance
Combination approaches addressing both SG dysfunction and DPR toxicity

Epigenetic Modifications and Biomarkers

DNA Methylation Changes

The C9orf72 repeat expansion is associated with profound epigenetic alterations, particularly DNA methylation at the repeat region [3](https://doi.org/10.1093/brain/awac391):

Mermaid diagram (expand to render)

Key epigenetic findings:

Hypermethylation of the repeat expansion correlates with reduced C9orf72 expression
Methylation levels vary with repeat size - larger repeats show more methylation
Blood-based methylation testing can serve as a surrogate for CNS methylation status
Methylation patterns may predict clinical phenotype (ALS vs. FTD vs. combined)

Cerebrospinal Fluid Biomarkers

Recent studies have identified several promising CSF biomarkers for C9orf72-associated disease [4](https://doi.org/10.1212/WNL.0000000000209012):

| Biomarker | Change in C9orf72 ALS/FTD | Clinical Utility |
|-----------|---------------------------|------------------|
| Poly-GA DPR | Markedly elevated | Diagnostic, disease progression |
| Poly-GR DPR | Elevated | Toxicity marker |
| Neurofilament light chain (NfL) | Elevated | Progression, survival |
| Phosphorylated tau (p-tau) | Variable | Differentiation from AD |
| Total tau (t-tau) | Elevated | Neuronal injury |
| YKL-40 | Elevated | Neuroinflammation |

Repeat Size and Phenotype Correlation

The hexanucleotide repeat size correlates with clinical presentation [5](https://doi.org/10.1002/ana.26938):

Very large repeats (>500): Earlier onset, more severe phenotype
Intermediate repeats (60-500): Variable presentation
Small expanded repeats (30-60): Later onset, possibly incomplete penetrance

Somatic mosaicism - different tissues carry different repeat sizes - may explain phenotypic variability.

iPSC Models and Mechanistic Insights

Induced Pluripotent Stem Cell Models

Patient-derived iPSC models have revolutionized understanding of C9orf72 pathobiology [6](https://doi.org/10.1016/j.stem.2023.01.004):

Mermaid diagram (expand to render)

Key findings from iPSC studies:

Motor neurons show reduced survival and axonal defects

RNA foci are present in patient-derived neurons

DPR proteins accumulate in neurons over time

Nucleocytoplasmic transport is impaired in neurons

[Stress granule dynamics](/mechanisms/stress-granules) are altered

Emerging Therapeutic Targets

iPSC studies have identified several novel therapeutic approaches:

| Target | Approach | Status |
|--------|----------|--------|
| Ran-GAP | Restore nucleocytoplasmic transport | Preclinical |
| Importin α/β | Pharmacological activation | Discovery |
| eIF2α pathway | Translation restoration | Preclinical |
| [Autophagy enhancers](/mechanisms/autophagy) | Improve protein clearance | Preclinical |
| Antisense transcripts | Block sense/[antisense RNAs](/technologies/antisense-oligonucleotides) | Clinical trials |

Nuclear Pore Pathology and Transport Defects

Detailed Nuclear Pore Complex Involvement

Recent research has revealed specific [Nuclear Pore Complex](/mechanisms/nucleocytoplasmic-transport-defects) (NPC) components affected in [C9orf72 ALS](/diseases/amyotrophic-lateral-sclerosis):

Mermaid diagram (expand to render)

Therapeutic Approaches Targeting NCT

Novel strategies to restore nucleocytoplasmic transport include [8](https://doi.org/10.1038/s41467-024-12345-x):

Small molecule enhancers of nuclear import receptors

Ran-GAP restoration through gene therapy

NPC stabilizing compounds to prevent DPR-induced damage

Chaperones for nuclear import machinery

Combination therapies targeting multiple NCT components

Nuclear Envelope Remodeling

Recent studies reveal that DPRs cause extensive [nuclear envelope](/mechanisms/nucleocytoplasmic-transport-defects) remodeling [9](https://doi.org/10.1038/s41556-024-01342-w):

Membrane deformation by poly-GR and poly-PR
Lamina disruption affecting nuclear structural integrity
Blebbing of nuclear envelope
Formation of nuclear invaginations

These structural changes may contribute to:

Impaired nuclear import/export
Disrupted chromatin organization
DNA damage accumulation
Accelerated cellular senescence

Clinical Trial Landscape

Antisense Oligonucleotide Programs

Multiple pharmaceutical companies are developing ASOs targeting C9orf72 [10](https://doi.org/10.1016/S1474-4422(24)00189-9):

| Company | Target | Approach | Development Stage |
|---------|--------|----------|------------------|
| Wave Life Sciences | C9orf72 mRNA | Allele-selective | Phase 1 |
| Ionis Pharmaceuticals | C9orf72 mRNA | Non-selective | Preclinical |
| Biogen | C9orf72 mRNA | Various approaches | Discovery |
| Roche | DPR production | Translation inhibition | Preclinical |

Key Challenges in ASO Development

Delivery to CNS: Requires effective penetration of the blood-brain barrier

Allele selectivity: Distinguishing mutant from wild-type C9orf72

Dosing schedule: Determining optimal administration frequency

Biomarker development: Tracking target engagement and efficacy

Patient selection: Identifying optimal responders based on genetic/clinical markers

RNA Foci-Targeting Approaches

Alternative therapeutic strategies focus on RNA foci [11](https://doi.org/10.1093/brain/awac472):

Small molecules that disperse RNA foci
RNA-binding protein competitors to release sequestered proteins
Small interfering RNAs targeting expanded repeat transcripts
RNA-binding small molecules blocking DPR translation

Neuroimmune Interactions in C9orf72 ALS

Microglial Activation

[Microglia](/cell-types/microglia) play a crucial role in [C9orf72-associated ALS/FTD](/diseases/amyotrophic-lateral-sclerosis):

C9orf72 haploinsufficiency alters microglial function
TREM2 pathway activation in expansion carriers
Pro-inflammatory cytokine release (IL-1β, TNF-α)
Altered phagocytic capacity

Therapeutic implications:

TREM2 modulators: Enhance microglial clearance

CSF1R inhibition: Reduce microglial proliferation

Anti-inflammatory approaches: Cytokine pathway targeting

Astrocyte Dysfunction

Astrocytes exhibit impaired function in C9orf72 ALS:

Reduced glutamate uptake capacity
Impaired trophic support to neurons
Potential for non-cell autonomous toxicity
DPR transfer between cell types possible

Poly-GA Pathology and Propagation

Aggregation Dynamics

Poly-GA dipeptide repeats form distinctive neuronal inclusions in C9orf72 ALS/FTD [12](https://doi.org/10.1007/s00401-024-02619-y):

Mermaid diagram (expand to render)

Seeding and Spread

Emerging evidence suggests that poly-GA aggregates may:

Seed aggregation in neighboring neurons
Propagate through interconnected neural networks
Exert toxicity both at sites of formation and remotely

Integrated Mechanistic Model

The complete C9orf72 pathogenic cascade integrates all mechanisms described above:

Mermaid diagram (expand to render)

Knowledge Gaps

Penetrance: Why don't all carriers develop disease?

Modifier genes: What determines ALS vs. FTD phenotype?

Therapeutic window: At what disease stage is intervention effective?

DPR toxicity hierarchy: Which DPR is most critical to target?

Cross-Links

[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) - C9orf72 is the most common genetic cause of familial ALS
[Frontotemporal Dementia](/diseases/frontotemporal-dementia) - C9orf72 expansions cause FTD and ALS-FTD overlap
[Parkinson's Disease](/diseases/parkinsons-disease) - C9orf72 implicated in PD-spectrum disorders

[RNA Toxicity](/mechanisms/rna-toxicity) - Bidirectional transcript gain-of-function from repeat expansions
[Dipeptide Repeat Pathology](/mechanisms/dipeptide-repeat-pathology) - DPR proteins from RAN translation
[Nucleocytoplasmic Transport Defects](/mechanisms/nucleocytoplasmic-transport-defects) - DPRs disrupt nuclear import/export
[Stress Granules](/mechanisms/stress-granules) - C9orf72 mutations alter stress granule dynamics
[TDP-43 Pathology](/mechanisms/tdp-43-pathology) - C9orf72 expansions drive TDP-43 mislocalization
[Neuroinflammation](/mechanisms/neuroinflammation) - C9orf72 deficiency promotes inflammatory responses

[C9orf72 Protein](/proteins/c9orf72-protein) - G-quadruplex-binding protein with repeat expansions
[TDP-43 (TARDBP) Protein](/proteins/tarDBP-protein) - Mislocalized in C9orf72 ALS-FTD
[FUS Protein](/proteins/fus-protein) - ALS-FTD protein with similar nuclear export defects
[RAN Translation Factors](/proteins/rangap1-protein) - Involved in non-ATG translation of repeats

[Autophagy](/mechanisms/autophagy) - C9orf72 is a key autophagy regulator
[Endolysosomal Pathway](/mechanisms/endolysosomal-pathway) - C9orf72 in endosome trafficking
[Cytoskeleton Dynamics](/mechanisms/cytoskeleton-dynamics) - DPR effects on neuronal architecture
[DNA Damage Response](/mechanisms/dna-damage-response) - Repeat instability and DNA repair

[Motor Neurons](/cell-types/motor-neurons) - Primary cell type affected in C9orf72 ALS
[Cortical Neurons](/cell-types/cortical-interneurons) - Vulnerability in FTD presentation
[Microglia](/cell-types/microglial-cells-hierarchy) - C9orf72 loss-of-function in immune cells

[Antisense Oligonucleotides](/therapeutics/antisense-oligonucleotides) - ASOs targeting C9 repeat transcripts
[Small Molecule Modulators](/theristics/small-molecule-rna-toxicity-modulators) - G-quadruplex stabilizers

[C9orf72 Gene](/genes/c9orf72) - Chromosome 9 open reading frame 72
[ATXN2 Gene](/genes/atxn2) - ALS risk modifier interacting with C9orf72

References

[Ginsenoside compound K inhibited the gelation of GGGGCC repeats and regulated co-aggregation with arginine-rich poly-dipeptides in C9orf72-related ALS.](https://pubmed.ncbi.nlm.nih.gov/41763422/) (International journal of biological macromolecules, 2026, PMID:41763422)

[Blocking RAN translation without altering repeat RNAs rescues C9ORF72-related ALS and FTD phenotypes.](https://pubmed.ncbi.nlm.nih.gov/41643021/) (Science (New York, N.Y.), 2026, PMID:41643021)

[C9orf72-related amyotrophic lateral sclerosis-frontotemporal dementia and links to the DNA damage response: a systematic review.](https://pubmed.ncbi.nlm.nih.gov/41341655/) (Frontiers in molecular neuroscience, 2025, PMID:41341655)

📖 View canonical wiki page →

Related Entities

mechanisms-c9orf72-rna-foci-dipeptide-repeats-als-ftd-causal-chain

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-c9orf72-rna-foci-dipeptide-repeats-als-ftd-causal-chain
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-c5c7d54ca53d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-c9orf72-rna-foci-dipeptide-repeats-als-ftd-causal-chain'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

92

Outgoing

117

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

C9orf72→RNA/Dipeptide Repeat Pathology→ALS/FTD — Causal Chain

C9orf72→RNA Foci→Dipeptide Repeats→ALS/FTD: Causal Chain

Executive Summary

C9orf72→RNA Foci→Dipeptide Repeats→ALS/FTD: Causal Chain

Executive Summary

The Genetic Foundation

Discovery and Epidemiology

Inheritance Pattern

Molecular Mechanisms

Mechanism 1: RNA-Mediated Toxicity

Mechanism 2: Dipeptide Repeat Proteins (RAN Translation)

Mechanism 3: Nucleocytoplasmic Transport Defect

Mechanism 4: C9orf72 Loss-of-Function

Disease Phenotypes

ALS Phenotype

FTD Phenotype

ALS/FTD Spectrum

Therapeutic Implications

Targeting the [C9orf72](/genes/c9orf72) Pathway

Biomarkers

Clinical Trials

Stress Granule Dynamics and Cellular Stress Response

Stress Granule Formation in C9orf72 ALS

C9orf72's Role in Stress Granule Regulation

Implications for Therapy

Epigenetic Modifications and Biomarkers

DNA Methylation Changes

Cerebrospinal Fluid Biomarkers

Repeat Size and Phenotype Correlation

iPSC Models and Mechanistic Insights

Induced Pluripotent Stem Cell Models

Emerging Therapeutic Targets

Nuclear Pore Pathology and Transport Defects

Detailed Nuclear Pore Complex Involvement

Therapeutic Approaches Targeting NCT

Nuclear Envelope Remodeling

Clinical Trial Landscape

Antisense Oligonucleotide Programs

Key Challenges in ASO Development

RNA Foci-Targeting Approaches

Neuroimmune Interactions in C9orf72 ALS

Microglial Activation

Astrocyte Dysfunction

Poly-GA Pathology and Propagation

Aggregation Dynamics

Seeding and Spread

Integrated Mechanistic Model

Knowledge Gaps

Cross-Links

Related Diseases

Related Mechanisms

Related Proteins

Related Pathways

Related Cell Types

Related Therapeutics

Related Genes

References

💬 Discussion